GlassScriptPhysician profile
James Anthony Boudreau
NPI 1215923941
$12,359.31
in general payments reported to CMS, 2019-2025
64 companies · $1,975 in 2025
The $1,975 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $1,125 · 2021: $2,020 · 2022: $1,794 · 2023: $2,278 · 2024: $2,515 · 2025: $1,975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,768.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,106.74 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,116.24 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $884.68 | 2019-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $788.58 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $677.02 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $639.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $558.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $458.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $438.94 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $369.32 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Sanofi-Aventis U.S. LLC | $362.73 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $319.77 | 2019-2024 | Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.56 | 2019-2024 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $254.27 | 2019-2025 | Rexulti |
| Nestle Healthcare Nutrition INC. | $219.23 | 2021-2023 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boudreau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.